Quick Takeaways
- ORBIMED ADVISORS LLC filed SCHEDULE 13G for Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share (XLO).
- Disclosed ownership: 10%.
- Date of event: 31 Mar 2026.
ORBIMED ADVISORS LLC - 31 Mar 2026 SCHEDULE 13G Report for Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share (XLO)
- Filing Manager
- ORBIMED ADVISORS LLC
- Reporting Manager
- ORBIMED ADVISORS LLC
- Symbol
- XLO
- Shares outstanding
- 6,426,426 shares
- Disclosed Ownership
- 642,000 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13G
- Filing time
- 15 May 2026, 16:38:51 UTC
- Date of event
- 31 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"ORBIMED ADVISORS LLC disclosed 10% ownership in Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share (XLO) on 31 Mar 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2026, 16:38.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% | 642,000 | 0 | 642,000 | /s/ Carl L. Gordon | Carl L. Gordon/Member | |
| OrbiMed Capital GP X LLC | 7.5% | 481,500 | 0 | 481,500 | /s/ Carl L. Gordon | Carl L. Gordon/Member of OrbiMed Advisors LLC |